• Lu SX, de Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, Knorr DA, Greenbaum B, Elhanati Y, Hogg SJ, Chow A, Ghosh A, Xie A, Zmarin D, Cui D, Erickson C, Singer M, Cho H, Wang E, Lu B, Durham BH, Shah H, Chowell D, Gabel AM, Shen Y, Liu J, Jin J, Rhodes MC, Taylor RE, Molina H, Wolchok J, Merghoub T, Diaz Jr. LA, Abdel-Wahab O, Bradley RK.

    Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

    Cell 2021 Jul 22;184(15):4032-4047.e31. DOI: 10.1016/j.cell.2021.05.038

  • Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, Mailankody S, Lesokhin A, Shah U, Lu S*, Patel D, Derkach A, Wilkins C, Korde N.

    Comparison of Venous Thromboembolism Incidence in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib, Lenalidomide, Dexamethasone (RVD) or Carfilzomib, Lenalidomide, Dexamethasone (KRD) with Aspirin or Rivaroxaban Thromboprophylaxis

    British J. Hematol. 2021, in press. DOI: 10.1111/bjh.17772

  • Inoue D, Polaski JT, Taylor J, Castel P, Chen S, Kobayashi S, Hogg SJ, Hayashi Y, Bello Pineda JM, El Marabti E, Erickson C, Knorr K, Fukumoto M, Yamazaki H, Tanaka A, Fukui C, Lu SX*, Durham BD, Liu B, Wang E, Mehta S, Zakheim D, Garippa R, Chew GL, McCormick F, Bradley RK, Abdel-Wahab O.

    Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition.

    Nature Genetics 2021, Apr 12. PMID: 33846634. DOI: 10.1038/s41588-021-00828-9

  • Landgren O, Hultcrantz M, Diamond B, Lesokhin A, Mailankody S, Hassoun H, Tan C, Shah U, Lu SX*, Salcedo M, Werner K, Rispoli J, Caple J, Sams A, Verducci D, Jones K, Concepcion I, Ciardiello A, Chansakul A, Schlossman J, Tavitian E, Shekarkhand T, Harrison A, Piacentini C, Rustad E, Yellapantula V, Maclachlan K, Maura F, Landau H, Scordo M, Chung D, Shah G, Lahoud O, Thoren K, Murata K, Ramanathan L, Arcila M, Ho C, Roshal K, Dogan A, Derkach A, Giralt S, Korde N.

    Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma.

    JAMA Oncology 2021, April 18. DOI: 10.1001/jamaoncol.2021.0611

  • Eveillard M, Korde N, Ciardiello A, Diamond B, Lesokhin A, Mailankody S, Smith E, Hassoun H, Hultcrantz M, Shah U, Lu S*, Salcedo M, Werner K, Rispoli J, Mastey D, Landgren O, Thoren K.

    Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.

    Clin Chim Acta. 2021 Feb 2;516:136-141. PMID: 33545108. DOI: 10.1016/j.cca.2021.01.021

  • Korde N, Mastey D, Tavitian E, Mailankody S, Lesokhin A, Hassoun H, Smith EL, Lendvai N, Hultcrantz M, Shah U, Tan C, Lu S*, Diamond B, Salcedo M, Werner K, Jones K, Verducci D, Sams A, Peterson T, Chung DJ, Scordo M, Shah G, Lahoud O, Landau H, Arcila M, Ho C, Roshal M, Dogan A, Derkach A, Devlin SM, Giralt SA, Landgren O.

    Tailored Treatment to MRD Response: A Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using High Dose Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone.

    Am. J. Hematol. 2021 Mar 4. PMID: 33661527. DOI: 10.1002/ajh.26150

  • Landau HJ, Yellapantula V, Diamond BT, Rustad EH, Maclachlan KH, Gundem G, Medina-Martinez J, Ossa JA, Levine MF, Zhou Y, Kappagantula R, Baez P, Attiye M, Makohon-Moore A, Zhang L, Boyle EM, Ashby C, Blaney P, Patel M, Zhang Y, Dogan A, Chung DJ, Giralt S, Lahoud OB, Peled JU, Scordo M, Shah G, Hassoun H, Korde NS, Lesokhin AM, Lu S*, Mailankody S, Shah U, Smith E, Hultcrantz ML, Ulaner GA, van Rhee F, Morgan GJ, Landgren O, Papaemmanuil E, Iacobuzio-Donahue C, Maura F.

    Accelerated single cell seeding in relapsed multiple myeloma.

    Nat Commun. 2020 Jul 17;11(1):3617. PMID: 32680998 PMCID: PMC7368016

  • Hultcrantz M, Richter J, Rosenbaum C, Patel D, Smith E, Korde N, Lu S*, Mailankody S, Shah U, Lesokhin A, Hassoun H, Tan C, Maura F, Derkach A, Diamond B, Rossi A, Pearse RN, Madduri D, Chari A, Kaminetzky D, Braunstein M, Gordillo C, Davies F, Jagannath S, Niesvizky R, Lentzsch S, Morgan G, Landgren O.

    COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers.

    Blood Cancer Discovery 2020 Nov; 1(3):234-243. PMID: 32577667 PMCID: PMC7302217

  • Eveillard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, Hultcrantz M, Lu S*, Shah U, Hassoun H, Smith E, Lesokhin A, Mailankody S, Landgren O, Thoren K.

    Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

    Br. J. Haematol. 2020 Feb 5. PMID: 32026474 PMCID: PMC7275888

  • Durham BH, Rodrigo EL, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX*, Pastore A, Mandelker D, Birsoy O, Ulaner GA, Walsh M, Yabe M, Petrova-Drus K, Arcila ME, Ladanyi M, Solit DB, Berger MF, Hyman DM, Lacouture ME, Ki M, Dunkel I, López VS, Mora J, Haroche J, Emile JF, Decaux O, Geissmann F, Savvides SN, Drilon A, Diamond EL, Abdel-Wahab O.

    Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms.

    Nature Medicine. 2019 Dec;25(12):1839-1842. PMID: 31768065 PMCID: PMC6898787

  • Inoue D, Guo-Liang C, Liu B, Michael B, Pangallo J, D’Avino D, North K, Bitner L, Block A, Moore AR, Lee SC, Yoshimi A, Escobar-Hoyos L, Cho H, Taylor J, Lu SX*, Chen Y, Kadoch C, Abdel-Wahab O, Bradley RK.

    Spliceosomal disruption of the non-canonical BAF complex in cancer

    Nature. 2019 Oct;574(7778):432-436. PMID: 31597964 PMCID: PMC6858563

  • Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX*, Akhlaghi T, Kristinsson SY, Bjorkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I.

    Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

    JAMA Oncology 2019 Jul 18;5(9):1293-1301. PMID: 31318385 PMCID: PMC6646992

  • Pastore A, Gaiti F, Lu SX*, Brand RM, Kulm S, Chaligne R, Gu H, Huang KY, Stamenova EK, Beguelin W, Jiang Y, Schulman R, Kim KT, Alonso A, Allan JN, Furman RR, Gnirke A, Wu CJ, Melnick AM, Meissner A, Bernstein BE, Abdel-Wahab O, Landau DA.

    Corrupted Coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in chronic lymphocytic leukemia.

    Nature Communications. 2019 Apr 23;10(1):1874. PMID: 31015400 PMCID: PMC6478836

  • Wang E*, Lu SX*, Pastore A, Chen X, Imig J, Chun-Wei Lee S, Hockemeyer K, Ghebrechristos YE, Yoshimi A, Inoue D, Ki M, Cho H, Bitner L, Kloetgen A, Lin KT, Uehara T, Owa T, Tibes R, Krainer AR, Abdel-Wahab O, Aifantis I.

    Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.

    Cancer Cell. 2019 Mar 18;35(3):369-384.e7. PMID: 30799057 PMCID: PMC6424627

    * SHARED FIRST AUTHOR

  • Lee SC, North K, Kim E, Jang E, Obeng E, Lu SX*, Liu B, Inoue D, Yoshimi A, Ki M, Yeo M, zhang XJ, Kim MK, Cho H, Chung YR, Taylor J, Durham BH, Kim YJ, Pastore A, Monette S, Palacino J, Seiler M, Buonamici S, Smith PG, Ebert BL, Bradley RK, Abdel-Wahab O.

    Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.

    Cancer Cell 2018. 2018 Aug 13;34(2):225-241. PMID: 30107174 PMCID: PMC6373472

  • Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hüllein J, Walther T, Wang L, Lu SX*, Oakes CC, Tibes R, Haferlach T, Taylor BS, Tallman MS, Berger MF, Park JH, Zenz T, Abdel-Wahab O.

    Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.

    Blood. 2017 Oct 5;130(14):1644-1648. PMID: 28801450 PMCID: PMC5630011

  • Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX*, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O.

    Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

    Blood. 2017 Jul 27;130(4):397-407. PMID: 28576879 PMCID: PMC5533204

  • Jin S, Su H, Tran N, Song J, Lu S*, Li Y, Huang S, Abdel-Wahab O, Liu Y, Zhao X

    Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.

    PLOS One, 017 May 18;12(5):e0175523. PMID: 28545085 PMCID: PMC5436638

  • Lu SX, Willis L, Charbonneau-Allard A, Atallah R, Holland A, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg R, Macian F, Holmes KV, Beauchemin N, van den brink MR.

    Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity

    after experimental allogeneic bone marrow transplantation.

    PLOS One, 2011;6(7):e21611. PMID: 21760897 PMCID: PMC3130781

  • Lu SX, Na IK, Terwey TH, Alpdoagan O, Bautista JL, Smith OM, Suh D, King C, Kochman A, Hubbard VM, Rao UK, Yim N, Liu C, Laga AC, Murphy GF, Jenq RR, Zakrzewski JL, Holland AM, Penack O, Dykstra LA, Bampoe K, Perez L, Furie B, Furie BC, van den Brink MR.

    Absence of P-selectin in Recipients of Allogeneic Bone Marrow Transplantation Ameliorates Experimental Graft-versus-Host-Disease.

    J. Immunol. 2010 Aug 1;185(3):1912-9. PMID: 20622117 PMCID: PMC3752704

  • Na IK*, Lu SX*, Goldberg G, King C, Smith OM, Yim N, Rao U, Suh D, Teisch L, Merkley S, Lin J, van den Brink MR.

    The cytolytic molecules FasL, TRAIL, and the trafficking molecules CCR9 and 7 integrin, PSGL-1, and Ceacam1 are required for thymic graft-versus-host disease after experimental murine allogeneic bone marrow transplantation.

    J. Clin. Invest. 2010 Jan;120(1):343-56. PMID: 19955659 PMCID: PMC2798682

    * SHARED FIRST AUTHOR

  • Penack O, Henke E, Suh D, King CG, Smith OM, Na IK, Holland AM, Ghosh A, Lu SX*, Jenq RR, Liu C, Murphy GF, Lu T, May C, Scheinberg DA, Gao DC, Mittal V, Heller G, Benezra R, van den Brink MR.

    Inhibition of Neovascularization Simultaneously Ameliorates Graft-versus-host-Disease and Decreases Tumor Growth.

    J. Natl. Cancer Inst. 2010 Jun 16;102(12):894-908. PMID: 20463307 PMCID: PMC2886094

  • Penack O, Smith OM, Cunningham-Bussel A, Liu X, Rao U, Yim N, Na IK, Holland AM, Ghosh A, Lu SX*, Jenq RR, Liu C, Murphy GF, Brandl K, Ubeda-Morant C, Pamer EG, van den Brink MR.

    NOD2 regulates Dendritic Cell Function during Graft-versus-Host-Disease.

    J. Exp. Med. 2009 Sep 28;206(10):2101-10. PMID: 19737867 PMCID: PMC2757869

  • Rotolo JA, Stancevic B, Lu SX*, Zhang J, Suh D, King CW, Kappel LW, Murphy GF, Liu C, Fuks ZR, van den Brink MR, Kolesnick R.

    Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease.

    Blood. 2009 Oct 22;114(17):3693-706. PMID: 19666872 PMCID: PMC2766684

  • Jenq RR, King C, Volk C, Suh D, Smith OM, Holland A, Lu SX*, Zakrzewski J, Goldberg G, Diab A, Alpdogan O, Penack O, Na I, Kappel L, Wolchok J, Houghton AN, Perales M, van den Brink MR.

    Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses following murine allogeneic bone marrow transplantation.

    Blood. 2009 Feb; 113(7):1574-80. PMID: 19011222 PMCID: PMC2644085

  • Lu SX, Alpdogan O, Lin J, Balderas R, Campos R, Wang X, Gao G, Suh D, King C, Chow M, Smith OM, Hubbard VM, Bautista L, Cabrera-Perez J, Zakrzewski J, Kochman A, Chow A, Altan-Bonnet G, van den Brink MR.

    STAT-3 and ERK 1/2 phosphorylation are critical for T cell alloactivation and Graft-Versus-Host-Disease.

    Blood. 2008 Dec; 112(13):5254-5258. PMID: 18838616 PMCID: PMC2597618

  • Alpdogan O, Lu SX, Patel N, McGoldrick S, Suh D, Budak-Alpdogan T, Smith OM, Grubin J, King C, Goldberg G, Hubbard VM, Kochman A, van den Brink MR.

    Rapidly Proliferating CD44hi Peripheral T cells Undergo Apoptosis and Delay Post-transplant T cell Reconstitution After Allogeneic Bone Marrow Transplantation.

    Blood. 2008 Dec; 112(12):4755-4764. PMID: 18815289 PMCID: PMC2597141

  • Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX*, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Zúñiga-Pflücker JC, Lu C, van den Brink MR.

    Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.

    Nat. Biotechnol. 2008 Apr; 26(4):453-61. PMID: 18376399 PMCID: PMC2731996

  • Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S*, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR.

    IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.

    J. Immunol. 2007 Aug; 179(3):1669-80. PMID: 17641033 DOI: 10.4049/jimmunol.179.3.1669

  • Borsotti C, Franklin AR, Lu SX*, Kim TD, Smith OM, Suh D, King CG, Chow A, Liu C, Alpdogan O, van den Brink MR.

    Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity.

    Blood. 2007 Jul; 110(2):783-6. PMID: 17395784 PMCID: PMC1924485

  • Zakrzewski JL, Kochman AA, Lu SX*, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Smith OM, Grubin J, Patel N, Chow A, Cabrera-Perez J, Radhakrishnan R, Diab A, Perales MA, Rizzuto G, Menet E, Pamer EG, Heller G, Zúñiga-Pflücker JC, Alpdogan O, van den Brink MR.

    Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.

    Nat. Med. 2006 Sep;12(9):1039-47. PMID: 16936725 DOI: 10.1038/nm1463

  • Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S*, Miles RC, Sakaguchi S, Houghton AN, van den Brink MR.

    Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

    J. Immunol. 2006 Jun 1;176(11):6434-42. PMID: 16709800. DOI: 10.4049/jimmunol.176.11.6434

  • Alpdogan O, Hubbard VM, Smith OM, Patel N, Lu S*, Goldberg GL, Gray DH, Feinman J, Kochman AA, Eng JM, Suh D, Muriglan SJ, Boyd RL, van den Brink MR.

    Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration.

    Blood. 2006 Mar 15;107(6):2453-60. PMID: 16304055 PMCID: PMC1895735

  • Waldman E, Lu SX*, Hubbard VM, Kochman AA, Eng JM, Terwey TH, Muriglan SJ, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR.

    Absence of 7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.

    Blood. 2006 Feb 15;107(4):1703-11. PMID: 16291587 PMCID: PMC1895413

  • Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, Ramirez-Montagut T, Eng JM, Muriglan SJ, Heller G, Murphy GF, Liu C, Budak-Alpdogan T, Alpdogan O, van den Brink MR.

    CCR2 is required for CD8-induced graft-versus-host disease.

    Blood. 2005 Nov 1;106(9):3322-30. PMID: 16037386 PMCID: PMC1895329